PRX 167700

Drug Profile

PRX 167700

Alternative Names: PRO VAP-1 inh; PRX 167700H; PRX167700

Latest Information Update: 27 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Biotechnology
  • Developer Proximagen
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory pain

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 20 Sep 2016 Phase-II clinical trials in Inflammatory pain (Adjunctive treatment) in Hungary (PO, Tablet) (EudraCT2016-001443-39)
  • 15 Feb 2016 Phase-II development in Inflammatory pain is ongoing in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top